Back to search results

Radiation for EBV-Associated Nasopharyngeal Carcinoma

This study is looking at a new way to give radiation therapy for Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (a type of head and neck cancer). It compares two types of Intensity-Modulated Radiation Therapy (IMRT), an advanced radiation treatment that targets tumors precisely. One type is standard IMRT, and the other is "response-guided" IMRT, which adjusts based on how well initial chemotherapy works. The goal is to see if the response-guided approach can be just as effective while potentially reducing side effects like hearing loss and dental problems. You might be able to join if you have confirmed EBV-associated nasopharyngeal carcinoma. The study will measure how many participants are alive without their cancer progressing two years after radiation.

Study design
This interventional study plans to enroll 66 participants. It compares two different approaches to Intensity-Modulated Radiation Therapy (IMRT).
What's involved
You would undergo IMRT, radiographic imaging procedures, and provide blood samples for biospecimen collection. The duration of participation is not fully specified, but primary outcomes are measured up to 26 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for progression-free survival for up to 26 months after radiation. Other outcomes like overall survival and side effects will be assessed at 1 and 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06682442

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Recruiting
NAAges 18+InterventionalTreatment
University of California, San Francisco
~66 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Intensity-Modulated Radiation Therapy (IMRT)Radiographic ImagingBiospecimen Collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression-Free Survival Rate (PFS) at 2 years post radiation
Measured over Up to 26 months

Conditions

Nasopharyngeal Carcinoma
Stage III Nasopharyngeal Carcinoma AJCC v8
Stage IVA Nasopharyngeal Carcinoma AJCC v8
Nasopharyngeal Cancer
Nasopharyngeal Cancer Stage

Explore related trials

Nasopharyngeal CarcinomaX-linked Lymphoproliferative Syndrome 1

NCT06682442

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California, San Francisco

    San Francisco, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sue Yom, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Imani Dunn
[email protected]
877-827-3222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have histologically or cytologically confirmed (from primary lesion and/or lymph nodes) nasopharyngeal carcinoma.
Participants must have Epstein Barr virus (EBV)-associated nasopharyngeal carcinoma, defined as detectable (\> 0 copies/mL) circulating plasma EBV DNA on a qualitative or quantitative polymerase chain reaction (PCR)-based test.
Stage III-IVA disease (American Joint Committee on Cancer \[AJCC\], 8th edition \[ed.\]) with no evidence of distant metastasis at the time of diagnosis based upon all 3 of the following minimum diagnostic workup criteria:
History/physical examination by a medical oncologist or clinical oncologist or radiation oncologist or otolaryngology (ENT);
Evaluation of tumor extent with either one of the following:
MRI with contrast of the face, nasopharynx, and neck or CT with contrast of the face, nasopharynx and neck with ≤ 3 mm contiguous slices and bone windows to evaluate base of skull involvement; or
MRI of the nasopharynx and PET/CT (with contrast) of the neck
Imaging to rule out distant metastasis:
CT scan with contrast of the chest and abdomen (required) and the pelvis (optional) or a total body PET/CT scan (non-contrast PET/CT is acceptable); and
Only if clinically indicated: Bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)
Started or planning to start platinum-based induction systemic therapy.
Planning to receive intensity modulated radiation therapy (IMRT) with concurrent, platinum-based systemic therapy during radiation.
Use of adjuvant (post-chemoradiation) immunotherapy is permitted.
Age \>=18 years.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 50%).
Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy are eligible for this trial.
For individuals with evidence of chronic hepatitis B virus (HBV) infection: must be on suppressive therapy, if indicated.
For individuals with a history of hepatitis C virus (HCV) infection: must be currently on treatment, or must have been treated and cured.
Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Because the radiation therapy used in this trial is known to be teratogenic, individuals of reproductive potential must agree to use adequate contraception (e.g., hormonal or barrier methods, abstinence) for the duration of study participation and for at least 60 days after the last administration of radiation therapy. Should a study participant or their partner become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.
Ability to understand and willingness to sign a written informed consent document.

Exclusion

Prior systemic chemotherapy for nasopharyngeal carcinoma, other than induction chemotherapy (IT); note that prior chemotherapy for a different cancer is permitted
Prior radiotherapy to the nasopharynx or surrounding involved areas that would result in overlap of radiation therapy fields
Has participated in a study of an investigational product and received treatment with an investigational drug or used an investigational device within 4 weeks prior to the first dose of treatment
Severe, active comorbidity, defined as any of the following:
Major medical or psychiatric illness that, in the treating investigator's opinion, would interfere with the completion of therapy and follow-up or interfere with a full understanding of the risks and potential complications of the therapy
Unstable angina, congestive heart failure, or peripheral vascular disease requiring hospitalization within the last 12 months; or other cardiac compromise that in the judgment of the treating investigator will preclude safe administration of study treatment
Chronic obstructive pulmonary disease (COPD) exacerbation or other respiratory illness requiring hospitalization within 30 days prior to registration, or which would preclude safe administration study therapy in the opinion of the treating investigator
Active, untreated infection and/or acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Because the radiation therapy used in this trial is known to be teratogenic, individuals of child-bearing potential must have documentation in their medical record of a negative pregnancy test
Has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause)
Has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries)
Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study activities or interfere with participant safety or study endpoints

What this trial measures

  • Progression-Free Survival Rate (PFS) at 2 years post radiationUp to 26 months

    PFS is defined as the proportion of participants alive without progression of disease from the first day of radiotherapy to progression or death by any cause, whichever occurs first, assessed up to 2 years after the last day of radiation therapy. The Kaplan-Meier method will be used to estimate the PFS rate along with a 90% confidence interval.